FDA Remove Clinical Hold On Phase 2 And 3 Trials Of COVAXIN In US
On Monday, 23rd May 2022, Ocugen, biotechnology company announced that, Food and Drug Administration (FDA) of the United States has now lifted the clinical hold on the Phase 2 and Phase 3 trials of the company for the COVAXIN corona virus vaccine in the United States. Dr. Shankar Musunuri, co-founder and chief executive officer and […]
Continue Reading